Cargando…

Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation

AIMS: Atrial fibrillation (AF) is associated with higher mortality. Biomarkers may improve the understanding of key pathophysiologic processes in AF that lead to death. Using a new multiplex analytic technique, we explored the association between 268 biomarkers and cardiovascular (CV) death in antic...

Descripción completa

Detalles Bibliográficos
Autores principales: Pol, Tymon, Hijazi, Ziad, Lindbäck, Johan, Oldgren, Jonas, Alexander, John H, Connolly, Stuart J, Eikelboom, John W, Ezekowitz, Michael D, Granger, Christopher B, Lopes, Renato D, Yusuf, Salim, Siegbahn, Agneta, Wallentin, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302885/
https://www.ncbi.nlm.nih.gov/pubmed/34358298
http://dx.doi.org/10.1093/cvr/cvab262
_version_ 1784751733697675264
author Pol, Tymon
Hijazi, Ziad
Lindbäck, Johan
Oldgren, Jonas
Alexander, John H
Connolly, Stuart J
Eikelboom, John W
Ezekowitz, Michael D
Granger, Christopher B
Lopes, Renato D
Yusuf, Salim
Siegbahn, Agneta
Wallentin, Lars
author_facet Pol, Tymon
Hijazi, Ziad
Lindbäck, Johan
Oldgren, Jonas
Alexander, John H
Connolly, Stuart J
Eikelboom, John W
Ezekowitz, Michael D
Granger, Christopher B
Lopes, Renato D
Yusuf, Salim
Siegbahn, Agneta
Wallentin, Lars
author_sort Pol, Tymon
collection PubMed
description AIMS: Atrial fibrillation (AF) is associated with higher mortality. Biomarkers may improve the understanding of key pathophysiologic processes in AF that lead to death. Using a new multiplex analytic technique, we explored the association between 268 biomarkers and cardiovascular (CV) death in anticoagulated patients with AF. METHODS AND RESULTS: A case–cohort design with 1.8- to 1.9-year follow-up. The identification cohort included 517 cases and 4057 randomly selected patients from ARISTOTLE. The validation cohort included 277 cases and 1042 randomly selected controls from RE-LY. Plasma collected at randomization was analysed with conventional immunoassays and the OLINK proximity extension assay panels: CVDII, CVDIII, and Inflammation. Association between biomarkers and CV death was evaluated using Random Survival Forest, Boruta, and adjusted Cox-regression analyses. The biomarkers most strongly and consistently associated with CV death were as follows (hazard ratio for inter-quartile comparison [95% CI]): N-terminal pro-B-type natriuretic peptide [NT-proBNP; 1.63 (1.37–1.93)], cardiac troponin T [cTnT-hs; 1.60 (1.35–1.88)], interleukin-6 [IL-6; 1.29 (1.13–1.47)], growth differentiation factor-15 [GDF-15; 1.30 (1.10–1.53)], fibroblast growth factor 23 [FGF-23; 1.21 (1.10–1.33)], urokinase receptor [uPAR; 1.38 (1.16–1.64)], trefoil factor 3 [TFF3; 1.27 (1.10–1.46)], tumour necrosis factor receptor 1 [TNFR1; 1.21 (1.01–1.45)], TNF-related apoptosis-inducing ligand receptor 2 [TRAILR2; 1.18 (1.04–1.34)], and cathepsin L1 [CTSL1; 1.22 (1.07–1.39)]. CONCLUSION: In this comprehensive screening of 268 biomarkers in anticoagulated patients with AF, the underlying mechanisms most strongly associated with CV death were cardiorenal dysfunction (NT-proBNP, cTnT-hs, CTSL1, TFF3), oxidative stress (GDF-15), inflammation (IL-6, GDF-15), calcium balance, vascular and renal dysfunction (FGF-23), fibrinolysis (suPAR), and apoptosis (TNFR1, TRAILR2). These findings provide novel insights into pathophysiologic aspects associated with CV death in AF. CLINICALTRIALS.GOV IDENTIFIER: NCT00412984 and NCT00262600.
format Online
Article
Text
id pubmed-9302885
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-93028852022-07-22 Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation Pol, Tymon Hijazi, Ziad Lindbäck, Johan Oldgren, Jonas Alexander, John H Connolly, Stuart J Eikelboom, John W Ezekowitz, Michael D Granger, Christopher B Lopes, Renato D Yusuf, Salim Siegbahn, Agneta Wallentin, Lars Cardiovasc Res Original Article AIMS: Atrial fibrillation (AF) is associated with higher mortality. Biomarkers may improve the understanding of key pathophysiologic processes in AF that lead to death. Using a new multiplex analytic technique, we explored the association between 268 biomarkers and cardiovascular (CV) death in anticoagulated patients with AF. METHODS AND RESULTS: A case–cohort design with 1.8- to 1.9-year follow-up. The identification cohort included 517 cases and 4057 randomly selected patients from ARISTOTLE. The validation cohort included 277 cases and 1042 randomly selected controls from RE-LY. Plasma collected at randomization was analysed with conventional immunoassays and the OLINK proximity extension assay panels: CVDII, CVDIII, and Inflammation. Association between biomarkers and CV death was evaluated using Random Survival Forest, Boruta, and adjusted Cox-regression analyses. The biomarkers most strongly and consistently associated with CV death were as follows (hazard ratio for inter-quartile comparison [95% CI]): N-terminal pro-B-type natriuretic peptide [NT-proBNP; 1.63 (1.37–1.93)], cardiac troponin T [cTnT-hs; 1.60 (1.35–1.88)], interleukin-6 [IL-6; 1.29 (1.13–1.47)], growth differentiation factor-15 [GDF-15; 1.30 (1.10–1.53)], fibroblast growth factor 23 [FGF-23; 1.21 (1.10–1.33)], urokinase receptor [uPAR; 1.38 (1.16–1.64)], trefoil factor 3 [TFF3; 1.27 (1.10–1.46)], tumour necrosis factor receptor 1 [TNFR1; 1.21 (1.01–1.45)], TNF-related apoptosis-inducing ligand receptor 2 [TRAILR2; 1.18 (1.04–1.34)], and cathepsin L1 [CTSL1; 1.22 (1.07–1.39)]. CONCLUSION: In this comprehensive screening of 268 biomarkers in anticoagulated patients with AF, the underlying mechanisms most strongly associated with CV death were cardiorenal dysfunction (NT-proBNP, cTnT-hs, CTSL1, TFF3), oxidative stress (GDF-15), inflammation (IL-6, GDF-15), calcium balance, vascular and renal dysfunction (FGF-23), fibrinolysis (suPAR), and apoptosis (TNFR1, TRAILR2). These findings provide novel insights into pathophysiologic aspects associated with CV death in AF. CLINICALTRIALS.GOV IDENTIFIER: NCT00412984 and NCT00262600. Oxford University Press 2021-08-06 /pmc/articles/PMC9302885/ /pubmed/34358298 http://dx.doi.org/10.1093/cvr/cvab262 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Pol, Tymon
Hijazi, Ziad
Lindbäck, Johan
Oldgren, Jonas
Alexander, John H
Connolly, Stuart J
Eikelboom, John W
Ezekowitz, Michael D
Granger, Christopher B
Lopes, Renato D
Yusuf, Salim
Siegbahn, Agneta
Wallentin, Lars
Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation
title Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation
title_full Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation
title_fullStr Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation
title_full_unstemmed Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation
title_short Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation
title_sort using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302885/
https://www.ncbi.nlm.nih.gov/pubmed/34358298
http://dx.doi.org/10.1093/cvr/cvab262
work_keys_str_mv AT poltymon usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation
AT hijaziziad usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation
AT lindbackjohan usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation
AT oldgrenjonas usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation
AT alexanderjohnh usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation
AT connollystuartj usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation
AT eikelboomjohnw usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation
AT ezekowitzmichaeld usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation
AT grangerchristopherb usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation
AT lopesrenatod usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation
AT yusufsalim usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation
AT siegbahnagneta usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation
AT wallentinlars usingmultimarkerscreeningtoidentifybiomarkersassociatedwithcardiovasculardeathinpatientswithatrialfibrillation